Please login to the form below

Not currently logged in
PMLiVE Top Pharma List

Data by

Global Data


Revenue 2014


The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of AstraZeneca's 2013 sales performance.

AZ and MSD win FDA priority review for Lynparza in breast cancer

AZ and MSD win FDA priority review for Lynparza in breast cancer

The PARP inhibitor - co-developed and co-commercialised by AstraZeneca (AZ) and Merck &Co - is under consideration for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have been ... Sean Bohen, executive vice president,

AZoNetwork appoints chief operating officer

AZoNetwork appoints chief operating officer Based at AZoNetwork’s headquarters in Manchester, James brings with him over 25 years’industry experience working in medical and scientific communications for companies such as AstraZeneca, where he held various

CHMP recommends Teva's generic version of Astellas' Advagraf

CHMP recommends Teva's generic version of Astellas' Advagraf AstraZeneca received a positive opinion for an extension to its glucose-lowering injectable Bydureon (exenatide).

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Pfizer could raise ‘up to $15bn’ from consumer unit sale of failed merger attempts with AstraZeneca and Allergan, the takeovers of Hospira and cancer specialist Medivation, and the divestment of Hospira’s infusions unit.

AZ starts pursuit of lung cancer indication for Imfinzi

AZ starts pursuit of lung cancer indication for Imfinzi AstraZeneca has filed for approval of its PD-L1 inhibitor Imfinzi in lung cancer, its first filing for the cancer immunotherapy in the EU.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Astra Zeneca
Global revenue 2014
1: Novartis
2: Pfizer
3: Roche
4: Sanofi
5: Merck & Co.
6: Johnson & Johnson
7: GlaxoSmithKline
8: AstraZeneca
9: Gilead Sciences
10: Takeda
11: AbbVie
12: Amgen
13: Teva
14: Lilly
15: Bristol-Myers Squibb
16: Bayer
17: Novo Nordisk
18: Astellas
19: Boehringer Ingelheim
20: Actavis
21: Otsuka
22: Daiichi Sankyo
23: Biogen Idec
24: Baxter
25: Merck KGaA
US revenue 2014
1: Gilead Sciences
2: Johnson & Johnson
3: Pfizer
4: Roche
5: Novartis
6: Amgen
7: Merck & Co.
8: Sanofi
9: AbbVie
10: Actavis
11: AstraZeneca
12: GlaxoSmithKline
13: Lilly
14: Bristol-Myers Squibb
15: Novo Nordisk
Oncology revenue 2014
1: Roche
2: Novartis
3: Celgene
4: Johnson & Johnson
5: Bristol-Myers Squibb
6: Lilly
7: Takeda
8: AstraZeneca
9: Merck & Co.
10: Amgen
11: Pfizer
12: Astellas
13: Bayer
14: Otsuka
15: Sanofi
16: Merck KGaA
17: Eisai
18: AbbVie
19: Pharmacyclics
20: Incyte
CNS revenue 2014
1: Pfizer
2: Biogen Idec
3: Novartis
4: Otsuka
5: Teva
6: Johnson & Johnson
7: Lilly
8: Merck KGaA
9: AstraZeneca
10: Shire
11: Bristol-Myers Squibb
12: UCB
13: Lundbeck
14: Eisai
15: GlaxoSmithKline
16: Sanofi
17: Mylan
18: Indivior
19: Actavis
20: Bayer
Cardiovascular revenue 2014
1: AstraZeneca
2: Sanofi
3: Merck & Co.
4: Daiichi Sankyo
5: Pfizer
6: Novartis
7: Bayer
8: Takeda
9: Boehringer Ingelheim
10: Astellas
11: Actelion
12: Johnson & Johnson
13: Shionogi
14: United Therapeutics
15: Bristol-Myers Squibb
16: Gilead Sciences
17: Otsuka
18: Roche
19: Lilly
20: The Medicines Company
Metabolic revenue 2014
1: Novo Nordisk
2: Sanofi
3: Merck & Co.
4: Lilly
5: AstraZeneca
6: Takeda
7: Novartis
8: Amgen
9: Bayer
10: Merck KGaA
11: Salix Pharmaceuticals
12: AbbVie
13: Dainippon Sumitomo Pharma
14: Kyowa Hakko Kirin
15: Mitsubishi Tanabe

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit

Featured jobs

Subscribe to our email news alerts


Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

How Can We Make Payer Communications Really Sing?
With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...
So how do you really engage with patients?
The most valuable insights from patient engagement are the most unexpected ones. Simple things, which may seem unimportant to you, may be the key to making patients’ lives easier and...